ERBB2 and breast cancer: This may be potentially due to several reasons including inclusion of AS II HR+/HER2- BC as an advanced stage, which could lead to better than expected OS compared to those with strictly AS III disease, and inclusion of HER2+ disease in AS I, unfavorable histology comparison group, which may also increase OS and/or recurrence-free survival rates compared to TNBC since over two-thirds of patients with HER2+ disease received anti-HER2-directed therapy, which has shown to improve clinical outcomes.